ERR
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
CSN25739 | ZK 164015 | 177583-70-9 | ZK 164015 is an antagonist of estrogen receptor. It inhibits 17β-estradiol stimulation of luciferase activity with IC50 of 0.025 μM. |
CSN23201 | Y134 | 849662-80-2 | Selective estrogen receptor modulator (SERM), selective for ERα |
CSN28481 | PROTAC ERRα Degrader-2 | 2306388-85-0 | PROTAC ERRα Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader. |
CSN28500 | PROTAC ERRα Degrader-1 | 2306388-84-9 | PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an PROTAC estrogen-related receptor alpha (ERRa) degrader. |
CSN28497 | PROTAC ER Degrader-4 | 2361114-15-8 | PROTAC ER Degrader-4 is a PROATC estrogen receptor (ER) degrader, binding to ER with an IC50 of 0.8 nM. PROTAC ER Degrader-4 induces ER degradation in MCF-7 cells with an IC50 of 0.3 nM. |
CSN26190 | Propyl pyrazole triol | 263717-53-9 | Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%). PPT also exerts anti-diabetic effects in mouse models. |
CSN19099 | Resmetirom | 920509-32-6 | MGL-3196 is a selective thyroid hormone receptor agonist with EC50s of 0.21 and 3.74 M for TR and TR respectively. |
CSN24502 | MB-07811 (VK-2809) | 852948-13-1 | MB-07811 is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist with cholesteroland triglycerides lowering activity. |
CSN12274 | Liquiritigenin | 578-86-9 | Liquiritigenin is an estrogenic compound which fuctions as a selective agonist of the estrogen receptor ER and an partial agonist of ER. It also has choleretic effect. Liquiritigenin is a flavanone extracted from glycyrrhiza uralensis with antitumour action. |
CSN22924 | H3B-5942 | 2052128-15-9 | H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively. |
CSN26546 | GSK5182 | 877387-37-6 | GSK5182 is a specific inverse agonist for estrogen-related receptor γ. |
CSN26648 | Giredestrant tartrate | 2407529-33-1 | Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity[1]. |
CSN26647 | Giredestrant | 1953133-47-5 | Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1]. |
CSN19421 | Genistin | 529-59-9 | Genistin is a isoflavone which has a role in blocking cell cycle and inducing apoptosis. It is also a modulator of estrogen receptor. Genistin can be isolated from the seeds of glycine max (L.) merr. and used as negative control of genistein. |
CSN21091 | GDC-0927 | 1642297-01-5 | GDC-0927, also known as SRN-927, is a next-generation oral SERD, appears to have greater potential than GDC-0810 to be a best-in-class SERD molecule. |
CSN24207 | GDC-0927 HCl | 1642297-02-6 | GDC-0927 is a next-generation oral SERD. |
CSN25302 | Estrogen receptor modulator 1 | 63676-22-2 | Estrogen receptor modulator 1 is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. It has been found to be both estrogenic and antiproliferative in ER-positive endocrine-resistant breast cancer cell lines that overexpress protein kinase C alpha (PKCα). |
CSN24698 | PROTAC ERRα ligand 2 | 2306388-57-6 | ERRα degrader ligand 4a block the protein-protein interaction of ERRα with PGC-1α coactivator with IC50 value of 5.67nM in a TR-FRET assay. |
CSN27511 | ERRα antagonist-1 | 1072145-33-5 | ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC50 values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1. |
CSN12284 | (-)-(S)-Equol | 531-95-3 | Equol, a non-steroidal estrogen, is a selective agonist of ER. It is produced from the metabolism of the isoflavonoid phytoestrogen daidzen by human intestinal microflora. |
CSN12352 | Calycosin | 20575-57-9 | Calycosin, a phytoestrogen, is a partial agonist of ER and a calcium channel blocker. It also shows prevention of reperfusion injury. Calycosin can be isolated and purified from the herb of Astragalus membranaceus Bge. var. mongholicus with anti-oxidative activity. |
CSN21522 | Bifluranol | 34633-34-6 | Bifluranol is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol that has been used as an antiandrogen in the United Kingdom in the treatment of benign prostatic hyperplasia. |
CSN27628 | Camizestrant | 2222844-89-3 | AZD-9833 is a potent and orally active estrogen receptor (ER) antagonist. AZD-9833 is used for the study of ER+ HER2-advanced breast cancer[1]. |
CSN28406 | ARV-471 | 2614417-52-4 | ARV-471 is the first-clinical-entered ERα PROTAC degrader with DC50 of ~1nM. It degrades clinically-relevant ESR1 variants (Y537S and D538G) and inhibits growth of cell lines expressing those variants. |
CSN32897 | Amcenestrant | 2114339-57-8 | Amcenestrant is an orally active, nonsteroidal and selective estrogen receptor degrader (SERD). |
CSN26189 | (E/Z)-4-Hydroxytamoxifen | 68392-35-8 | Afimoxifene is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. Afimoxifene is a potent activator of ER and has been shown to have a higher affinity for estrogen receptors compared to tamoxifen. It has significant dose and time-dependent direct effects to alter the contractile function of isolated adult rat cardiac myocytes. |
CSN21921 | (R)-Equol | 221054-79-1 | (R)-Equol is an agonist of both ERα and ERβ with Kis of 27.4 and 15.4 nM, respectively. |
CSN38973 | GW7604 | 195611-82-6 |